Mounjaro through the NHS: what the official guidance says and who qualifies right now

What NICE approved, and why NHS access is being drip-fed rather than opened up at once

NICE published its recommendation for tirzepatide (Mounjaro) in December 2024, following the evidence from the SURMOUNT clinical programme, particularly the SURMOUNT-1 trial published in the New England Journal of Medicine, which showed around 20–21% average body-weight reduction at the highest dose over 72 weeks. That's a meaningful result, and NICE agreed.

The reason access is phased, rather than immediately available to everyone who could benefit, comes down to workforce capacity and NHS budget planning. Prescribing infrastructure has to be built. Wraparound lifestyle support (dietitian input, physical activity coaching) has to be commissioned alongside the medicine. So NHS England designed a staged rollout: the highest-need patients first, then progressively broader groups over the following years.

The full NICE appraisal and its implementation timeline are set out at NICE TA1026. It's worth reading if you want chapter and verse on how the recommendation is structured.

Who the NHS is prescribing Mounjaro to right now

From June 2025, the first NHS cohort opened: adults with a BMI of 40 or above, plus four or more of five specific weight-related conditions. Those conditions are high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. Meeting one or two of them isn't enough at this stage.

A second cohort activated in June 2026, broadening access to adults with a BMI of 35 to 39.9 who also have four or more of the same conditions. The criteria are still demanding. A third phase, expected around March 2027, will cover BMI of 40 or above with three conditions. Each stage depends on the previous one being properly embedded.

For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, BMI thresholds are set 2.5 kg/m² lower throughout (so 37.5 instead of 40, for example) in line with UK guidance on ethnic background and metabolic risk.

Even within a qualifying cohort, access isn't automatic. Your GP practice has to have opted into the new prescribing contract, and every patient taking part in NHS treatment must engage with the wraparound diet and activity support. If you're unsure where your practice stands, it's worth asking directly. Our page on Mounjaro via your GP on the NHS has more on what that conversation looks like.

What happens if you don't qualify for NHS Mounjaro yet

Most people asking this question right now won't meet the current NHS criteria. A BMI of 40 with four serious comorbidities is a high bar, by design. That leaves a large group of people who could clinically benefit from tirzepatide but have no NHS route yet.

For that group, private prescription through a GPhC-registered pharmacy is how treatment is currently accessible. There's no referral needed, no waiting list, and the clinical assessment still happens, a real prescriber reviews your answers, not an automated system. You can read more about what that process involves on our page covering NHS and private routes together, or explore how Mounjaro is priced privately if cost is the main question on your mind.

One practical note: if you order before noon on a weekday, prescriptions are reviewed the same day, and approved treatment goes out with DPD for next-working-day delivery. That's the kind of timeline the NHS, understandably, can't offer.

If you want to know more about the treatment itself before making any decision, our full Mounjaro overview covers how tirzepatide works, its side-effect profile, and what to expect from treatment. And if the NHS route is still the one you want to pursue, our detailed eligibility guide walks through the criteria in plain language so you can work out where you stand.

A note on pharmacists and who can actually prescribe Mounjaro

Tirzepatide is a prescription-only medicine. In the UK, it can be prescribed by a doctor or (as is common in regulated online services) a pharmacist who holds an Independent Prescriber qualification. A standard dispensing pharmacist cannot prescribe it; that distinction matters when you're looking at who is reviewing your case.

At nume, every consultation is read and decided on by a GPhC-registered Independent Prescriber, not software. Our guide to pharmacist prescribing explains what that qualification involves and why it matters for safety. If you have broader questions about how the service works, our FAQs are a good place to start before you speak to anyone.

Once you've got a clear picture of your options, speaking to our prescribers is a straightforward next step, there's no obligation, and the consultation is free.